1Department of Radiation Oncology, Stanford University, Stanford, California. 2Stanford Cancer Institute, Stanford University, Stanford, California.

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...

1Instituto de Investigación Sanitaria HM Hospitales, Madrid, Spain. 2Department of Basic Medical Sciences, Institute of Applied Molecular Medicine (IMMA), Facultad de Medicina, Universidad San Pablo ...

1Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois. *Corresponding Author: Hilary A. Kenny, Department of Obstetrics and Gynecology, ...

In a small investigator-initiated study, patients with early-stage mismatch repair–deficient solid cancers and minimal residual disease following surgery—determined by circulating tumor DNA—were found ...

The investigational HER2-selective tyrosine kinase inhibitor zongertinib appears remarkably effective in patients with HER2-mutant non–small cell lung cancer. Robust, durable responses were seen in ...

1Department of Pathology, Stanford University School of Medicine, Stanford, California.

According to data announced today at the American Association for Cancer Research Annual Meeting 2025, Merck’s anti-PD-1 mAb pembrolizumab (Keytruda) led to significant improvements in event-free ...

Renowned scientist Douglas Hanahan, PhD, discusses the legacy of The Hallmarks of Cancer, the challenge of adaptive resistance, and how insights into the tumor microenvironment and cancer neuroscience ...

Daniel Drucker, a pioneer in GLP-1 receptor–agonist research, discusses the history of the drugs, their wide-ranging benefits, and how they might benefit patients with cancer. On April 28, 2005, the ...

Search for other works by this author on: ...

St. Jude Children's Research Hospital, Memphis, TN.